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Myriad biomedical data are available today and bring 
with them a need to “translate” those data into mean-
ingful information that can be used to accelerate clin-
ical and translational science and drive innovations 
in clinical care and drug discovery. We describe the 
work of The Biomedical Data Translator Consortium 
to develop a platform that supports the translation of 
data into knowledge by applying inferential methods 
to a graph representation of biomedical entities and 
their relationships.
FROM VISION TO TRANSLATION
The collection and analysis of “big data” are delivering sig-
nificant benefits across multiple sectors of society, includ-
ing social media, finance, marketing and advertising, fraud 
prevention, and the physical sciences.1–3 Although many 
of these efforts have yet to demonstrate improvements to 
public welfare, the promise of big data for the public good 
is widely anticipated.
This promise is perhaps most broadly felt in translational 
research and clinical care. However, although the amount 
and diversity of biomedical data have dramatically in-
creased in recent years, tangible benefits derived from big 
data to the practice of medicine have been slower to arrive. 
For example, the Precision Medicine Initiative has made re-
markable progress, with several examples of success,4 but 
universal approaches for tailoring treatments to individual 
patients have yet to be developed. In addition, randomized 
controlled clinical trials, once the “gold standard” of clinical 
research and practice, are now widely recognized as lim-
ited due to their inherent inability to target investigational 
treatments and therapies to patients who are most likely to 
demonstrate maximum benefit (and minimum harm) based 
on individual biomolecular profiles. Indeed, this short-
coming underlies the “basket trial” design that is gaining 
popularity, and demonstrating early success, in oncology 
research.5
The National Center for Advancing Translational Sciences 
(NCATS), a center within the National Institutes of Health, 
launched the Biomedical Data Translator program in October 
2016 in an effort to overcome existing challenges and pro-
vide a complementary solution (Table S1). The goal of the 
initial feasibility assessment is to design and prototype a 
“Translator” system capable of integrating existing biomed-
ical data sets or “Knowledge Sources” and “translating” 
those data into insights that can accelerate translational re-
search, support clinical care, and leverage clinical expertise 
to drive research innovations.
A HIGH- LEVEL OVERVIEW OF UNIVERSAL 
TRANSLATION
As envisioned, the Translator system will facilitate the use 
of disparate biomedical data to solve a range of challenges 
(Figure 1). Among other goals, the Translator aims to en-
able what has been termed “data- driven clinical regroup-
ing” of patients in an effort to refine current definitions 
of disease and identify groups of patients who are likely 
to respond or not respond to specific treatments. These 
groupings are expected to facilitate the identification of 
patients with shared molecular and cellular biomarkers 
and thereby generate new biomedical hypotheses, pro-
mote translational discovery, facilitate efficient clinical- trial 
design, and inform clinical decision making. In this man-
ner, the Translator system is intended to supplement, not 
replace, traditional approaches to clinical and translational 
science.
To achieve these ambitious goals, the Translator will 
identify and target multiple Knowledge Sources deemed 
relevant to a user inquiry and apply a variety of computa-
tional approaches to translate data from those Knowledge 
Sources into new knowledge, with associated provenance 
and a level of confidence. The user will then be empowered 
with new information that can be used directly to answer 
the inquiry or to generate testable hypotheses. The com-
putational approaches will yield results or “artifacts” that 
may have obvious clinical or biological relevance, as well 
as output that may not seem to be relevant, as determined 
by subject- matter experts. The artifacts of questionable 
relevance will be maintained by the Translator not only to 
improve performance of the system over time, but also 
to facilitate serendipity: unexpected discoveries that are 
revealed as a result of combining new Knowledge Sources 
or computational approaches, generating new inquiries, 
or revealing heretofore unexpected relationships between 
biological mechanisms. Through this high- level iterative 
approach, the Translator system is expected to demon-
strate improvement over time and ultimately achieve the 
important goal of disease- agnostic data- driven clinical re-
grouping—hence, “universality.”
DRIVING DEMONSTRATION USE CASES
Demonstration use cases and targeted inquiries have driven 
research and development of the prototype Translator sys-
tem. Specifically, two demonstration use cases have been 
developed thus far: pediatric asthma, a common disease 
influenced by a plethora of genes and socio- environmental 
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exposures; and Fanconi anemia, a rare disease caused by 
defects in relatively few genes and influenced by select 
socio- environmental exposures. These two use cases will 
serve to ensure that the Translator is developed with the 
flexibility needed to address inquiries of relevance to each 
extreme of the disease- frequency spectrum. The specific 
questions that are being asked include questions whose 
answers are largely known, but are necessary to test the 
nascent Translator system, such as: Is exposure to airborne 
particulate matter associated with asthma exacerbations 
and responsiveness to treatment? Do genes and gene 
products causal to Fanconi anemia interact with genes 
and gene products related to aldehyde metabolism? Other 
questions are more exploratory and are designed to push 
the boundaries of the prototype system, such as: Which 
medications are currently prescribed to pediatric patients 
with an asthma- like phenotype who are responsive to treat-
ment despite high levels of exposure to airborne particulate 
matter? What drug targets block the biological pathways 
that are activated by particulate matter? What genes show 
high phenotypic similarity to the 11 Fanconi anemia core 
complex genes? What genes and pathways are uniquely 
targeted by hematopoietic- stem- cell- transplantation- 
conditioning drugs that are well tolerated vs. poorly toler-
ated by patients with Fanconi anemia?
Importantly, the use- case questions were selected spe-
cifically because answering them requires a variety of data 
sources and a series of translational tasks, each involving 
varying degrees of reasoning. Translator team members ac-
knowledge the critical need to identify any “gaps” in data 
sources and systematically evaluate any answers gener-
ated by the prototype Translator system. To this end, select 
questions will serve as a validation set for the prototype sys-
tem. These questions will be complex and require a variety 
of data sources and reasoning- based translational tasks, 
but they will have “ground- truth” answers that can be used 
to evaluate output from the prototype system. Moreover, 
some of the questions will not be related to the use cases, 
Figure 1 Conceptual overview of Biomedical Data Translator functionality.
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which will help to prevent overfitting of the prototype sys-
tem. Furthermore, team members are developing sophisti-
cated analytic approaches to rank and score all answers and 
quantify uncertainty and confidence in results. Finally, team 
members are engaging subject-matter experts to provide 
feedback on the ranking and scoring of answers in order to 
iteratively improve the prototype system.
KNOWLEDGE SOURCES
To translate these inquiries, the prototype Translator is 
designed to tap into a rich set of “Knowledge Sources,” 
including (but not limited to): data on clinical signs and 
symptoms, diagnostic measures and tests, diagnoses and 
other disease constructs, treatments and drug exposures, 
and exome or genome pedigrees, available from patient 
medical records and clinical ontologies; data on environ-
mental exposures (e.g., airborne pollutants and ozone), 
available from the US Environmental Protection Agency; 
data on socio- environmental exposures (e.g., household 
income, access to transportation, and access to health 
insurance), available from the US Census Bureau; and ex-
perimental and mechanistic data on genetic variants, bio-
logical pathways, molecular and cellular anatomy, systems 
biology, and chemical structures and drug targets, avail-
able from a variety of open data sources. To date, over 40 
such Knowledge Sources have been developed through a 
collaboration of Translator institutions across the nation. 
Certain Knowledge Sources have proven to be more chal-
lenging to access and integrate than others (e.g., patient 
data), but Translator team members have worked creatively 
to overcome the challenges. As a striking example, we re-
cently identified an approach for revealing processed clini-
cal data in a regulatory- compliant manner that enables the 
open use of clinical data as part of the Translator program 
(see COHD and ICEES, Figure 2). Teams are also devel-
oping privacy- preserving analytic methods for summariz-
ing patient records.6 Successes and insights such as these 
were only made possible through the collaborative, inter-
disciplinary culture that the program has fostered and the 
unique skillsets and perspectives provided by individual 
team members.
KNOWLEDGE GRAPHS AND REASONERS
A prototype Translator framework and architecture have 
been developed for integrating semantically annotated 
Knowledge Sources and creating a data platform to sup-
port automated reasoning and serendipitous discovery 
of new “facts” or interesting and testable hypotheses 
(Figure 2). First, the application programming interfaces 
(APIs) of Knowledge Sources are catalogued directly with 
associated metadata in a unified “Translator API Registry” 
as an extension of the SmartAPI service standard.7 In ad-
dition, Knowledge Sources are wrapped generically as 
“Knowledge Beacons” using a standardized, semanti-
cally typed workflow for discovery of concepts and rela-
tionships. The BioLink data model serves to standardize 
the semantic structure of the data contained within the 
Knowledge Sources and thereby facilitate integration 
and automated reasoning. To achieve reasoning, a virtual 
“Knowledge Graph” integrates the data by connecting 
“nodes” or entity types with “edges” or predicates in the 
graph. The Knowledge Graph architecture is similar to the 
“Blackboard” architecture that was conceptualized more 
than 4 decades ago by researchers in artificial intelligence 
research as a general problem- solving approach to over-
come the challenges in multimodal problem solving.8 The 
Figure 2 High- level overview of prototype Translator system architecture. Abbreviations for Translator APIs: Big CLAM, Big Cell 
Line Association Miner; BioThings, BioThings Explorer; COHD, Columbia Open Health Data; DDOT, Data- Driven Ontology Toolkit 
plus disease ontologies; FA, Fanconi anemia; ginas, global ingredient archival system; ICEES, Integrated Clinical and Environmental 
Exposures Service; GO, Gene Ontology; MONDO, MONarch Disease Ontology; NDEx, Network Data Exchange; PGMs, probabilistic 
graphical models; SEES, Socio- Environmental Exposures Service; SemMedDB, Semantic MEDLINE DataBase. For additional 
information, including hyperlinks to Translator services, see Table S2.
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central idea is that multiple, distributed Knowledge Sources 
dynamically propose pieces of a translated user inquiry and 
posit that information to a virtual Knowledge Graph. One 
or more “Reasoners” then work collaboratively or inde-
pendently to apply analytic approaches to infer a complete 
or partial translation of the inquiry by generating infer-
ence “paths” across the nodes and edges contributed by 
the various Knowledge Sources. The Knowledge Sources 
themselves do not communicate with each other; rather, 
the Knowledge Graph is the only “shared knowledge.” The 
Reasoners then return ranked and scored potential trans-
lations with provenance and supporting evidence. The user 
is then able to evaluate the translations and supporting ev-
idence and provide feedback to the Reasoners, thus pro-
moting continuous improvement of the prototype system.
MOTIVATING FACTORS
The Translator program currently is in the feasibility phase. 
The program’s early success will help to ensure the long- term 
viability of the project, although we recognize that sustaining 
cyberinfrastructure for science represents a significant chal-
lenge across funding agencies and scientific fields. However, 
the Translator effort is motivated by a number of observations 
and collective assertions of team members that we believe will 
encourage continued research and development of the pro-
totype Translator system. First, we assert that a single mono-
lithic data set that directly connects the complete set of clinical 
characteristics to the complete set of biomolecular features, 
including “- omics” data, will never exist because the number 
of characteristics and features is constantly shifting and ex-
ponentially growing. Second, even if such a single monolithic 
data set existed, all- vs.- all associations will inevitably succumb 
to problems with statistical power (i.e., the curse of dimension-
ality).9 Such problems will get worse, not better, as more and 
more clinical and biomolecular data are collected and become 
available. We also assert that there is no single language, soft-
ware or natural, with which to express clinical and biomolecular 
observations—these observations are necessarily and appro-
priately linked to the measurement technologies that produce 
them, as well as the nuances of language. The lack of a univer-
sal language for expressing clinical and biomolecular observa-
tions presents a risk of isolation or marginalization of data that 
are relevant for answering a particular inquiry, but are never 
accessed because of a failure in translation.
Based on these observations, our final assertion is that 
automating the ability to reason across integrated data 
sources and providing users who pose inquiries with a dos-
sier of translated answers coupled with full provenance and 
confidence in the results is critical if we wish to accelerate 
clinical and translational insights, drive new discoveries, 
facilitate serendipity, improve clinical- trial design, and ulti-
mately improve clinical care. This final assertion represents 
the driving motivation for the Translator system.
MOVING FORWARD
Why is the time right to build a Translator system? First, 
we have access to vast amounts of valuable clinical and 
biomolecular data, yet managing the data, integrating the 
data, analyzing the data, and extracting value from the data 
have proven to be both challenging and expensive. Second, 
the cultural and political climate is such that the public is 
demanding that researchers, clinicians, and funders de-
liver on their promise to use all data sources that have been 
generated at considerable public cost for the public good. 
A final, critical reason to move forward with the Translator 
system is that only recently have we had the data, the stan-
dards, the tools, the networks, the computing power, and 
the expertise to even conceptualize a Translator, let alone 
research and develop one.
Supporting Information. Supplementary information accom-
panies this paper on the Clinical and Translational Science website 
(www.cts-journal.com).
Table S1. The Biomedical Data Translator Consortium: teams and team 
members.
Table S2. Translator architecture: select Knowledge Sources.
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